Top

Published in:

01-01-2009 | Original Article

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

Authors: Divya Menon-Andersen, John T. Mondick, Bhuvana Jayaraman, Patrick A. Thompson, Susan M. Blaney, Mark Bernstein, Mason Bond, Martin Champagne, Michael J. Fossler, Jeffrey S. Barrett

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2009

Abstract

Background

Imatinib mesylate (Gleevec^®) is a small molecule tyrosine kinase inhibitor approved for use in the management of chronic myeloid leukemia in adults and children and in gastrointestinal stromal tumors in adults. Population pharmacokinetic (PPK) studies evaluating the effect of population covariates on the pharmacokinetics of imatinib and its active metabolite have been developed in adults with chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). However, this still remains to be described in children.

Purpose

The objectives of the analysis were to develop a PPK model of imatinib and its active metabolite, CGP74588, to describe exposure in children and young adults and to identify covariates that are predictors of variability in disposition.

Methods

Plasma concentrations from 26 subjects with Philadelphia (Ph+) leukemia (Phase I study) and 15 subjects with refractory solid tumors (Phase II study), who received oral imatinib at doses ranging from 260 to 570 mg/m², were available for the PPK analysis in NONMEM. Blood samples were drawn prior to dosing and over 24–48 h on days 1 and 8 of the studies. Covariates studied included weight, age, albumin, alanine aminotransferase and the study population.

Results

The pharmacokinetics of imatinib and CGP 74588 were well described by one and two compartment models, respectively. Total body weight was the only covariate found to significantly affect Cl/F and V/F. The final imatinib-CGP 74588 model is summarized as follows: CL/F _imatinib (L/h) = 10.8 × (WT/70)^0.75, V/F _imatinib (L) = 284 × (WT/70) and D1_{duration of zero order absorption,imatinib} (h) = 1.67 and CL/F _CGP 74588 (L/h) = 9.65 × (WT/70)^0.75, V1/F _CGP 74588 (L) = 11.6 × (WT/70), Q _CGP 74588 (L/h) = 2.9 × (WT/70)^0.75 and V2/F _CGP 74588 (L) = 256*(WT/70). Model evaluation indicated that the final model was robust and satisfactory.

Conclusions

Current imatinib dosing guidelines in pediatrics is based on the achievement of exposures consistent with doses known to be safe and efficacious in adults. Dose adjustments in children are guided empirically by the observance of drug-related toxicities. While, the pharmacokinetics of imatinib and its active metabolite, CGP 74588 in children are consistent with prior knowledge in adults, the model will form the basis to support the design of future trials, particularly with a view to managing toxicities and exploring dosing in this population.

Abdiu A, Wingren S, Larsson SE, Wasteson A, Walz TM (1999) Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and in vivo. Cancer Lett 141:39–45PubMedCrossRef

Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F (2002) High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 768:325–340PubMedCrossRef

Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN (2006) Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45:1077–1097PubMedCrossRef

Beal SL, Sheiner LB (1992) NONMEM users guides. NONMEM Project Group, University of California at San Francisco

Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC (2007) A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children’s oncology group study. Pediatr Blood Cancer

Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM, Bernstein M (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a children’s oncology group phase 1 study. Blood 104:2655–2660PubMedCrossRef

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935–942PubMed

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034–3038PubMed

de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A:ontogeny and drug disposition. Clin Pharmacokinet 37:485–505PubMedCrossRef

10.

Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691–3698PubMed

11.

Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G (2006) Pharmacokinetic–pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12:6073–6078PubMedCrossRef

12.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566PubMedCrossRef

13.

FDA (2003) FDA approves Gleevec for pediatric leukemia. FDA Consum 37(4):6

14.

Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, Peng B, Gross G (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503–1512PubMedCrossRef

15.

Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925–932PubMed

16.

Holford NH (2005) The visual predictive check—superiority to standard diagnostic plots. In: 2005 population approach group in Europe (PAGE) annual meeting, Pamplona, Spain

17.

Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC soft tissue and bone sarcoma group. Cancer Chemother Pharmacol 55:379–386PubMedCrossRef

18.

le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G, Dorken B, Ehninger G, Ottmann O, Jenke A, Bornhauser M, Schleyer E (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313–323PubMedCrossRef

19.

Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM (2004) Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res 10:2525–2529PubMedCrossRef

20.

Nikolova Z, Peng B, Hubert M, Sieberling M, Keller U, Ho YY, Schran H, Capdeville R (2004) Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 53:433–438PubMedCrossRef

21.

Novartis Pharma Stein AG (2003) Gleevec^® (imatinib mesylate): prescribing information [online]

22.

Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158–162PubMedCrossRef

23.

Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935–942PubMedCrossRef

24.

Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879–894PubMedCrossRef

25.

Ramalingam S, Lagattuta TF, Egorin MJ, Hayes MJ, Ramanathan RK (2004) Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. Pharmacotherapy 24:1232–1235PubMedCrossRef

26.

Savage DG, Antman KH (2002) Imatinib mesylate–a new oral targeted therapy. N Engl J Med 346:683–693PubMedCrossRef

27.

Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A (2005) Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia:results of a phase III study. Br J Clin Pharmacol 60:35–44PubMedCrossRef

28.

Sjoblom T, Shimizu A, O’Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61:5778–5783PubMed

29.

Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A (2000) Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 13:632–637PubMedCrossRef

30.

Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475–490PubMedCrossRef

31.

Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171–192PubMedCrossRef

Title: Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
Authors: Divya Menon-Andersen
John T. Mondick
Bhuvana Jayaraman
Patrick A. Thompson
Susan M. Blaney
Mark Bernstein
Mason Bond
Martin Champagne
Michael J. Fossler
Jeffrey S. Barrett
Publication date: 01-01-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0730-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2009

NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells

Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer

Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures

Administration of oxaliplatin to a pregnant woman with rectal cancer

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer